To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens. AbbVie’s Maviret ...

After revenues flattened in the first three months of the year, in the second quarter Gilead saw its total sales fall 6%, largely down to shrinking revenues from its HCV portfolio. Sales shrunk in ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

Gilead Sciences Inc. (NASDAQ ... mainstream over its much-publicized controversy involving Sovaldi in 2013, its $84,000 treatment for hepatitis C (hep C). The 12-week treatment was the world’s first ...